Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 399 record(s)

Req # A-2023-000318

Adverse Drug Reaction (ADR) for NALTREXONE. Report number: E2B_06248776. ADRs for HEPARIN. Report numbers: 001034285, 001034469.

Organization: Health Canada

23 page(s)
August 2023

Req # A-2023-000322

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103753-996, Findings Related to Drug Shortages from a Recent Public Opinion Research Survey.

Organization: Health Canada

27 page(s)
August 2023

Req # A-2023-000328

Adverse Drug Reactions (ADRs). Report numbers: E2B_04499568, E2B_06021664.

Organization: Health Canada

30 page(s)
August 2023

Req # A-2023-000330

Adverse Drug Reactions (ADRs). Report numbers: E2B_06251460, E2B_06255079, 001034496, 001033269, 001033828, 001031996, E2B_06206246, E2B_06211731, E2B_06221489, E2B_06240950.

Organization: Health Canada

114 page(s)
August 2023

Req # A-2023-000332

Adverse Drug Reactions (ADRs). Report numbers: E2B_06257918, E2B_06232891, E2B_06214010, E2B_06219585, E2B_06225938.

Organization: Health Canada

98 page(s)
August 2023

Req # A-2023-000336

Adverse Drug Reactions (ADRs) for MEZAVANT. Report numbers: 001032099, E2B_06211524. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_06234973, E2B_06257555, E2B_06223464, E2B_06234247, E2B_06234712, E2B_06233235, E2B_06202939.

Organization: Health Canada

101 page(s)
August 2023

Req # A-2023-000338

Adverse Drug Reactions (ADRs). Report numbers: E2B_06179247, E2B_06087973, E2B_06097866.

Organization: Health Canada

27 page(s)
August 2023

Req # A-2023-000342

Adverse Drug Reaction (ADR) for LANREOTIDE. Report number: E2B_06150154. ADR for CABOMETYX. Report number: 001032922.

Organization: Health Canada

15 page(s)
August 2023

Req # A-2023-000344

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103161-840.

Organization: Health Canada

7 page(s)
August 2023

Req # A-2023-000356

Adverse Drug Reactions (ADRs). Report numbers: E2B_06250623, 001033895, 001032057, E2B_06238976, 001031987, 001035819, E2B_06242635, E2B_06223152, E2B_06232387, 001034491.

Organization: Health Canada

331 page(s)
August 2023
Date modified: